Who
Mark W. Parrish
Director
Company insider
Files Form 4 as: Director, Omnicell; Director, Viatris; Director, Mylan II B.V; Director, Mylan; Director, Bausch Health Companies; CEO - Hscs, Cardinal Health.
In numbers
- Trades disclosed
- 187
- Buys
- 2
- Sells
- 4
- Bought
- $285K
- Sold
- $3.5M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 8 Nov 2006
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | OMCL OmnicellMedical Devices | SEC FORM 4 Code A | —4,845 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | OMCL OmnicellMedical Devices | SEC FORM 4 Code A | —4,845 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.49 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.492 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | OMCL OmnicellMedical Devices | SEC FORM 4 Code A | —6,828 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —23,660 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —772.84 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —773 at $0.00 | filing |
| 10 Dec 2024filed 12 Dec 2024 | OMCL OmnicellMedical Devices | SEC FORM 4 Sold | $568K12,000 at $47.30 | filing |
| 21 May 2024filed 23 May 2024 | OMCL OmnicellMedical Devices | SEC FORM 4 Code A | —6,143 at $0.00 | filing |
News
Reviewing Omnicell (NASDAQ:OMCL) & Baxter International (NYSE:BAX)OMCL · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Mark W. Parrish; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.